El futuro en el tratamiento del cáncer renal

44 / 64

NK Cell–Targeted Anti–Killer Cell Ig‐Like Receptor Ab. (Anti‐KIR)
Lirilumab in Combination With Nivolumab or Ipilimumab
Segal NH, et al. ESMO 2016; Vvier E, et al. Data not published